Diagnosis and Management of Medulloblastoma

Introduction to Medulloblastoma Diagnosis

The National Comprehensive Cancer Network (NCCN) guidelines state that tissue diagnosis through surgical resection is required to definitively diagnose medulloblastoma, obtain histopathologic confirmation, and perform critical molecular genetic characterization that determines risk stratification and treatment planning 1, 2
The primary goals of surgical intervention include obtaining adequate tissue for histopathologic diagnosis, performing molecular genetic characterization, achieving maximal safe resection, reducing tumor-associated mass effect, and providing relief from hydrocephalus 1, 2, 4, 5

Genome-wide DNA methylation with brain tumor classifier application, combined with next-generation sequencing, is now the gold standard for medulloblastoma diagnosis and subgroup classification 3, 6
This testing helps reduce diagnostic error, allows differential diagnosis with other posterior fossa tumors, distinguishes between Group 3 and Group 4 tumors, and identifies molecular subgroups (WNT, SHH, Group 3, Group 4) that have dramatically different prognoses and treatment implications 3, 6, 7

On MRI, medulloblastoma typically presents as a large, heterogeneous posterior fossa mass occupying the fourth ventricle or cerebellar hemisphere 4
The WNT subtype specifically shows intratumoral hemorrhage more frequently than other molecular subtypes 1

The NCCN recommends surgical resection with goals of gross total resection (GTR) or near-total resection (NTR) when safe, and resection with ≤1.5 cm² residual is acceptable in some settings 1, 8
Minimizing neurologic deficits is also a key consideration during surgical intervention 5

Tissue should be sent for standard histopathology, DNA methylation profiling, next-generation sequencing, IHC panel, and germline testing 1, 3, 5, 7

Risk stratification based on molecular findings directly impacts survival, with different prognoses for WNT-activated, SHH-activated, Group 3, and Group 4 tumors 4, 7, 8
Treatment intensity varies dramatically based on molecular subgroup and risk factors, affecting both radiation dose and chemotherapy regimens 2, 8